The QualityStocks Daily Thursday, January 27th, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(INDO) $5.8900 +110.36%

MarketBeat(GLPG) $65.3000 +22.47%

PennyStockProphet(STAL) $1.3100 +20.18%

The QualityStocks Daily Stock List

Marine Petroleum Trust (MARPS)

MarketBeat, TradersPro, Trade of the Week, MarketClub Analysis, TraderPower, QualityStocks and Louis Navellier reported earlier on Marine Petroleum Trust (MARPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marine Petroleum Trust is a royalty trust listed on the Nasdaq Global Select Market. Together with its subsidiary, Marine Petroleum Corporation, it operates as a royalty trust in the United States. The Company was established in 1956 under the laws of the State of Texas.

Marine Petroleum Corporation holds title to interests in properties subject to the Trust’s interest that are located offshore of Louisiana. Ninety-eight percent of all oil, natural gas, and other mineral royalties collected by Marine Petroleum Corporation, less the cost of receiving and collecting, are paid to the Trust. Marine Petroleum Trust is headquartered in Dallas, Texas.

Roughly 60 percent of Marine’s royalty revenues are attributable to oil and roughly 40 percent are attributable to natural gas. The royalty revenues received by Marine are affected by several factors. These include the producing capabilities of the wells, seasonal fluctuations in demand, as well as by changes in the market price for oil and natural gas.

The royalty revenues received by Marine are affected by a number of factors including the producing capabilities of the wells, seasonal fluctuations in demand, and by changes in the market price for oil and natural gas.

Marine Petroleum Trust (MARPS), closed Thursday’s trading session at $5.21, up 18.2747%, on 356,684 volume. The average volume for the last 3 months is 356,684 and the stock's 52-week low/high is $3.75/$8.98.

GigaMedia (GIGM)

PROFIT CONFIDENTIAL, Wall Street Resources, SmallCap Network, TradersPro, China Vesting, CoolPennyStocks, Daily Markets, MarketBeat, InvestorPlace, QualityStocks, Pennybuster, SmarTrend Newsletters, Stock Traders Chat, BullRally, StockEgg, PennyStocks24, StreetInsider, HotOTC, Greenbackers, MarketClub Analysis, Penny Detectives, Investment Contrarians, Daily Profit, MadPennyStocks, StockRich, Trading Markets, Stock Fortune Teller, PennyStockVille, Street Insider, PennyInvest, Wealth Insider Alert, TopStockAnalysts, The Street, Energy and Capital, FeedBlitz, The Momentum Traders Network, Hit and Run Candle Sticks, The Best Newsletters, Stockpalooza, Market FN, Stock Rich, Marketbeat.com, Stock Research Newsletter, MicroCap, Momentum Traders, Penny Invest, SmallCapNetwork, Zacks and InvestorsUnderground reported earlier on GigaMedia (GIGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GigaMedia Ltd (NASDAQ: GIGM) (FRA: GIFN) is a holding company that is engaged in the provision of various cloud computing services as well as the development, distribution and operation of online entertainment software and services to the online gaming industry, in particular, the casino and online poker industry.

GigaMedia Ltd is based in Taipei, Taiwan and was incorporated in October 1998. The firm operates in Taiwan, Macau, Hong Kong and the People’s Republic of China.

GigaMedia Ltd develops and licenses software for online gambling and operates its subsidiary; FunTown, a digital entertainment portal, which provides browser and mobile based casual games through the branded platform.

The GigaMedia portfolio is made up of a traditional Chinese tile based game popularly known as MahJong, multi-player role-player online games, online card games, casual table and card games as well as chance-based games like slots, Sic-Bo, horse racing, lotto and bingo. Additionally, the firm offers role-playing games and sports games like a male-oriented game known as Shinobi Master New Link; a female-oriented games called Akaseka; a story based game which targets female players known as Yume 100 and a multi-player online obstacle running game called Tales Runner. Under cloud computing, the firm operates and owns GigaCloud, a cloud computing solutions and services provider that is focused on the cloud services market for medium-sized and small enterprises in Taiwan.

GigaMedia Ltd recently entered into a purchase agreement with Aeolus Robotics Corporation, which is focused on the design and manufacture of intellectual robotics. Robotics and AI are believed to be game changers in almost every sector and with the industry set to grow rapidly in the future, good and profitable things are expected from this agreement.

GigaMedia (GIGM), closed Thursday’s trading session at $2.04, up 9.973%, on 89,850 volume. The average volume for the last 3 months is 89,850 and the stock's 52-week low/high is $1.75/$5.56.

Tiziana Life Sciences (TLSA)

StockMarketWatch, RedChip, TradersPro, BUYINS.NET, MarketClub Analysis, MarketBeat, Jon Markman’s Pivotal Point, Red Chip, QualityStocks and InvestorPlace reported earlier on Tiziana Life Sciences (TLSA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tiziana Life Sciences PLC (NASDAQ: TLSA) (OTC: TIZAF) (FRA: RTRB) is a clinical stage biotechnology firm that is focused on researching and developing pharmaceutical and biotechnological products for the treatment of autoimmune neurodegenerative disorders, chronic inflammatory ailments and cancers.

The firm is based in London, the United Kingdom and was founded in 2013, on November 4 by Gabriele Marco Antonio Cerrone. It serves patients in the United States and the United Kingdom.

The company is a subsidiary of Planwise Group Limited and operates as part of the Biotechnology research services industry.

The company’s product portfolio includes a human anti-CD3 monoclonal antibody, dubbed TZLS-401 (Foralumab), which was developed to help treat various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, type-1 diabetes, multiple sclerosis, Crohn’s disease and ulcerative colitis. Other candidates include an anti-interleukin-6 receptor monoclonal antibody for treating IL6-induced inflammation called TZLS-501 (Anti IL-6r); a multi-gene signature assay indicated for use by patients who’ve been diagnosed with ER+/HER2 negative breast cancers called StemPrintER and a small molecule inhibitor of Src and cyclin-dependent kinases, which is orally bioavailable and was developed to help treat hepatocellular carcinoma known as TZLS-201 (Milciclib). This compound is currently concluding phase 2 clinical trials for thymoma and/or epithelial thymic carcinoma in patients who’d been treated with chemotherapy prior to the trial.

The company recently revealed that the FDA has allowed the evaluation of Foralumab’s nasal administration in a secondary progressive multiple sclerosis patient. The candidate is a new approach that has the potential to offer a safe treatment for MS, which currently has no effective treatments. If successful, this candidate could revolutionize treatment for this debilitating ailment. In addition to this, the firm has filed an IND to enroll patients in a Hepatic Cellular Carcinoma exploratory trial.

Tiziana Life Sciences (TLSA), closed Thursday’s trading session at $0.8499, up 7.6504%, on 142,021 volume. The average volume for the last 3 months is 142,002 and the stock's 52-week low/high is $0.66/$4.99.

Orgenesis, Inc. (ORGS)

QualityStocks, Greenbackers, StockMarketWatch, Stock News Now, MarketBeat, StreetInsider, MarketClub Analysis, IRGnews Alert, Streetwise Reports, SmallCapNetwork, pastwellness.com, OTCPicks and BUYINS.NET reported earlier on Orgenesis, Inc. (ORGS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Orgenesis, Inc. is a fully-integrated cell therapy and contract development and manufacturing company. It has a novel therapeutic technology for the treatment of diabetes. The Company has expertise and unique experience in cell therapy development and manufacturing. OTCQB-listed, Orgenesis is based in Germantown, Maryland.

In addition, the Company has a fully-owned subsidiary contract manufacturing and development company - MaSTherCell S.A. (Belgian subsidiary). This subsidiary’s dedication is to cell therapy for advanced medicinal products. MaSTherCell (a full-service contract development and manufacturing organization (CDMO)) specializes in the delivery of optimized process industrialization capacities to cell therapy organizations

Furthermore, by way of its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).

Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company uses a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Through its Israeli subsidiary, Orgenesis continues to advance its innovative cell-based therapy, the Autologous Insulin Producing (AIP) cells, into clinical development.  AIP cells use the technology of 'cellular transdifferentiation' to transform an autologous adult liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell.

Orgenesis has demonstrated promising results in in-vitro and in-vivo studies using human liver tissues. It designed an efficient and clear work-plan to start clinical testing soon, allowing it to launch Phase I clinical trials following Food and Drug Administration (FDA) guidelines followed by the launch of Phase II clinical trials within a year.

Orgenesis previously entered into a number of strategic partnerships and joint venture (JV) agreements. It entered into a JV Agreement with CureCell; it is collaborating in the contract development and manufacturing of cell therapy products in Korea.

Orgenesis Ltd, its Israeli subsidiary, entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL and CureCell in 2016. KORIL will provide funding for a joint research and development project for the use of AIP cells for the treatment of diabetes.

Orgenesis also entered into a JV agreement with Atvio Biotech Ltd., an Israeli company. This agreement is to collaborate in the contract development and manufacturing of cell and virus therapy products in the field of regenerative medicine.

Orgenesis, Inc. (ORGS), closed Thursday’s trading session at $2.89, up 12.4514%, on 81,666 volume. The average volume for the last 3 months is 81,666 and the stock's 52-week low/high is $2.12/$8.30.

Ecoark Holdings, Inc. (ZEST)

QualityStocks and TopPennyStockMovers reported earlier on Ecoark Holdings, Inc. (ZEST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ecoark Holdings, Inc. is an AgTech company modernizing the post-harvest fresh food supply chain for a wide array of organizations. These include growers, suppliers, distributors, as well as retailers. The Company’s wholly-owned subsidiary, is Zest Labs™. Founded in 2011, Ecoark Holdings is based in San Jose, California. The Company lists on the OTC Markets Group’s OTCQB.

Zest Labs’™ headquarters is located in the heart of the Silicon Valley, close to many of the world’s most famous agricultural regions. This provides it with fast access to the unique insights and perspectives of growers, producers, and processors.

Zest Labs offers the Zest Fresh™ solution. This is an innovative approach to the quality management of fresh food. It is expressly designed to help substantially reduce the $161 billion amount of food loss the Unites States experiences each year. Through item-level monitoring and real-time predictive analytics, Zest Fresh enables customers to improve the freshness and quality of produce and proteins, realize significant cost savings, and also lessen food waste.

Ecoark Holdings’ Zest Fresh solution enables growers, packers, shippers, distributors, and retailers to proactively monitor and manage food freshness in the supply chain. This provides the ability to reduce waste by 50 percent or more and improve product margins by six percent or more.

Zest Fresh for Produce, Zest Fresh for Protein, and Zest Delivery solutions provide the members of the fresh food supply chain with the information and actionable insights they need to optimize the fresh food supply chain operations to decrease waste. Additionally, they provide the information and actionable insights they need to provide true transparency and supply chain visibility for food safety and authenticity, and the information and actionable insights they need to promote food and environmental sustainability. Moreover, they provide the information and actionable insights to improve operational efficiency, labor and asset utilization and reduce costs, and increase brand loyalty and create competitive advantage in the marketplace.

At the end of March 2020, Ecoark Holdings announced that it entered into a definitive agreement to purchase Banner Midstream Corp. from Banner Energy Services Corp. Banner Midstream has 4 operating subsidiaries: Pinnacle Frac Transport LLC, Capstone Equipment Leasing LLC, White River Holdings Corp, and Shamrock Upstream Energy LLC.

Trend Discovery Holdings is also a wholly-owned subsidiary of Ecoark Holdings. Trend Discovery invests in a select number of early stage start-ups each year as part of the fund’s Venture Capital strategy. They are open-minded investors with a founder-first mentality.

Ecoark Holdings has also announced that it completed an acquisition of certain energy assets from an energy company, whose identity will be released in the future, in the process of bankruptcy reorganization. The all-cash transaction, with a projected short-term payback, includes the transfer of 262 total wells in Mississippi and Louisiana, roughly 9,000 acres of active mineral leases, and significant drilling and production materials and equipment.

The 262 total wells include 57 active producing wells, 19 active disposal wells, 136 shut-in with future utility wells, and 50 shut-in pending plugging wells. Included in the assignment are four wells in the Tuscaloosa Marine Shale (TMS) formation.

Ecoark Holdings, Inc. (ZEST), closed Thursday’s trading session at $2.42, up 11.5207%, on 58,432 volume. The average volume for the last 3 months is 58,432 and the stock's 52-week low/high is $2.00/$18.00.

US Stem Cell Inc. (USRM)

QualityStocks, MarketBeat, Wall Street Mover, Promotion Stock Secrets, PoliticsAndMyPortfolio.com, Money Morning and Money Map Press reported earlier on US Stem Cell Inc. (USRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

US Stem cell Inc. (OTC: USRM) is a biotechnology firm that is engaged in discovering, developing and commercializing autologous cellular therapies for the treatment of vascular and autoimmune ailments, as well as acute and chronic heart damage.

The firm has its headquarters in Sunrise, Florida and was incorporated in 1999, on August 12th by Robert D. Lashinski and Howard J. Leonhardt. Prior to its name change in October 2015, the firm was known as Bioheart Inc. The firm serves consumers in the United States.

The company develops regenerative medicine and cellular therapies that prevent, treat and cure a range of illnesses. It operates through the VBI (Vet Biologics) and the SCT (US stem Cell Training) divisions. The company’s other business includes the distribution of regenerative medicine products as well as patient and physician-based regenerative medicine/cell therapy training services.

The enterprise’s product candidates include a patient-derived cell therapy dubbed AdipoCell, which has been developed to treat lower limb ischemia, chronic heart ischemia and acute myocardial infarction; and a clinical therapy known as MyoCell, which enhances cardiac function in patients with chronic heart failure and populates different regions of scar tissue in a patient’s heart with autologous muscle cells. It also develops a deflecting tip needle injection dubbed MyoCath, which is used to introduce cells into cardiac tissue during treatment procedures for congestive heart failure and chronic heart ischemia.

The firm plans to venture into animal health innovation by placing more focus on and expanding its veterinary division and participating in the consumer driven pet-care industry. This will be good for the firm’s growth and investments, given the trending movements of the pet industry and the pet industry’s expected growth.

US Stem Cell Inc. (USRM), closed Thursday’s trading session at $0.00725, up 0.138122%, on 1,050 volume. The average volume for the last 3 months is 1,050 and the stock's 52-week low/high is $0.0051/$0.08715.

Maptelligent Inc. (MAPT)

We reported earlier on Maptelligent Inc. (MAPT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Maptelligent Inc. (OTC: MAPT) is focused on the provision of a cloud-based geographic platform which integrates data from alarms, cameras, sensors and accountability systems to develop actionable intelligence on an intuitive map display.

The firm has its headquarters in Henderson, Nevada and was incorporated in 1974, on August 7th. The firm serves consumers around the globe.

The company is party to a strategic partnership with NSION Technologies, which entails providing secure situational awareness using IoT sensors and real time video data streaming technology.

The enterprise’s platform also offers access information relevant to sites and structures that improve situational awareness and emergency response. It also offers a suite of applications and maps which afford consumers the ability to manage and maintain data in a mobile environment. For instance, building engineers can use the platform to manage maintenance schedules for elements like extinguishers, pull stations and alarm panels, which require regular attention, as well as public safety to develop incident preplans associated with building floor plans. In addition to this, the enterprise provides a cloud content management solution which manages and stores data associated with security solutions, professional services for safety assessments and system integration services. It serves various entities and organizations which are at risk from emergency incidents and threats like hospitals, schools universities, ports and shopping malls.

The company recently entered into a partnership with the Interactive Tactical Group, which will provide a range of services to the company’s clients as well as more accurate and reliable information in the indoor mapping capability space to consumers. This will be good for its investments as well as its growth.

Maptelligent Inc. (MAPT), closed Thursday’s trading session at $0.008, up 11.1111%, on 15,300 volume. The average volume for the last 3 months is 15,300 and the stock's 52-week low/high is $0.0046/$0.33.

Crown Electrokinetics (CRKN)

QualityStocks, AwesomeStocks, StockStreetWire, Small Cap Firm, Fierce Analyst, StockWireNews and Mega Stock Alerts reported earlier on Crown Electrokinetics (CRKN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Crown ElectroKinetics Corp (NASDAQ: CRKN) is focused on the commercialization of electrokinetic technology.

The firm has its headquarters in Corvallis, Oregon and was incorporated in 2015, on April 20th by Timothy Koch, James Douvikas and Douglas B. Croxall. Prior to its name change in October 2017, the firm was known as 3D Nanocolor Corp. The firm serves consumers in the United States.

The enterprise develops and sells optical switching film which can be applied to the surface of glass or other rigid substrates like acrylic, to control opacity electronically. The film can also be embedded between sheets of smart glass powered by solar strips. The enterprise’s electro kinetic film technology, which is derived from microfluidic and ink technology, uses nanometer-sized particles of pigments which have been charged electrically and suspended in a liquid sandwiched between substrates coated with a transparent conductor oxide film. The film enables transitions between dark and clear, which allows individuals to prevent and/or manage glare, control the tint of the skylight, block out ultraviolet rays, decrease carbon emissions, and decrease the amount of heat entering the home. The enterprise’s offerings can be applied to a range of windows, including automotive sunroofs, residential windows and skylights and commercial buildings.

The company recently entered into an agreement with Hudson Pacific Properties, which involves the installation of energy-saving smart window inserts at some of the properties Hudson owns on the West Coast. This move will not only help Hudson Pacific reduce carbon emissions and energy consumption from cooling and heating systems by at least 25%, but also bring in additional revenue to Crown Electrokinetics and help extend the company’s consumer reach.

Crown Electrokinetics (CRKN), closed Thursday’s trading session at $2.77, up 0.362319%, on 27,310 volume. The average volume for the last 3 months is 27,310 and the stock's 52-week low/high is $2.3252/$6.09.

Cyteir Therapeutics (CYT)

StreetInsider, INO.com Market Report, The Street, Barchart, Zacks, Street Insider, Dividend Opportunities, InvestmentHouse, Marketbeat.com, StreetAuthority Daily, MarketBeat, The Online Investor, The Trading Report, FNNO Newsletters, Uncommon Wisdom, Coattail Investor and SmarTrend Newsletters reported earlier on Cyteir Therapeutics (CYT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyteir Therapeutics Inc. (NASDAQ: CYT) is a clinical-stage oncology firm that is focused on the development of new synthetic lethality therapeutics based off of the biology of DNA repair, to treat autoimmune illnesses and cancer.

The firm has its headquarters in Lexington, Massachusetts and was incorporated in June 2012 by Timothy Romberger and Kevin Mills. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm serves consumers around the globe.

The company is focused on the treatment of various chronic autoimmune disorders, solid tumors and hematological malignancies. Its products inhibit DNA damage repair and cause cancer cell death via synthetic lethality.

The enterprise’s precision oncology medicines target important DNA repair factors which cause ailing cells to self-destruct by DNA damage overload. They use an integrated drug development platform which regulates the imbalance between DNA repair and damage for the therapeutic effect to deliver small molecule therapeutics with various disease state applications. Its products include CYT-1853, which is an inhibitor of RAD51-mediated homologous recombination. It also develops a once-daily oral small molecule inhibitor of RAD51-mediated homologous recombination dubbed CYT-0851, a DNA repair pathway crucial for the survival of various cancers.

The company is focused on advancing its CYT-0851 formulation, which it believes has the potential to expand access to various tumor types. The success and approval of this formulation will not only benefit patients with cancer but also bring in more investments into the company, which will in turn, boost its growth.

Cyteir Therapeutics (CYT), closed Thursday’s trading session at $5.63, off by 7.0957%, on 77,996 volume. The average volume for the last 3 months is 76,735 and the stock's 52-week low/high is $5.40/$23.10.

Candel Therapeutics (CADL)

MarketBeat reported earlier on Candel Therapeutics (CADL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Candel Therapeutics Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical firm that is focused on developing and commercializing cancer immunotherapy drugs.

The firm has its headquarters in Needham, Massachusetts and was incorporated in 1999 by Estuardo Aguilar-Cordova. Prior to its name change in November 2020, the firm was known as Advantagene Inc. The firm serves consumers in the United States.

The company develops oncolytic viral immunotherapies using its viral immunotherapy platform which is based on genetically modified HSV (herpes simplex virus) and adenovirus constructs. Its engineered viruses induce immunogenic death via viral-mediated cytotoxicity in diseased cells, which releases tumor neo-antigens and creates a pro-inflammatory microenvironment at a patient’s injection site. The company’s preclinical models and clinical trials use its approach.

The enterprise’s product portfolio comprises of its oncolytic HSV product candidate dubbed CAN-3110, which has been designed to improve tumor cell elimination while minimizing toxicity in health tissues. This candidate is undergoing a phase 1 clinical trial and has been developed to treat recurrent high-grade glioma. It also develops an adenovirus product candidate known as CAN-2409 (aglatimagenebesadenovec), to treat pancreatic cancer and primary prostate cancer.

The firm recently entered into a collaboration with Bionaut Labs, which explores the use of microscale robots developed by Bionaut for the delivery of oncolytic viral immunotherapy agents developed by Candel to tumors in the brain. This strategic collaboration may improve outcomes for patients living with brain cancer, which will not only benefit patients but also encourage more investments into the firm, which will boost its growth.

Candel Therapeutics (CADL), closed Thursday’s trading session at $4.81, off by 15.3169%, on 49,876 volume. The average volume for the last 3 months is 49,876 and the stock's 52-week low/high is $4.81/$14.78.

Clearmind Medicine Inc. (CMNDF)

We reported earlier on Clearmind Medicine Inc. (CMNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF), a psychedelic drug company, has announced the third webinar in its Psychedelics for Alcoholism series. During this webinar, addiction specialist and world-renowned author Dr. Gabor Maté will talk on the effects of Alcohol Use Disorder, addition and trauma; the webinar will also discuss how Clearmind's patented portfolio has potential to be an effective treatment. A retired Vancouver physician and a member of the Order of Canada, Maté has authored four books that have been translated into nearly 30 languages. His next book, “The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture,” will be published in 2022. Other participants in the webinar include Clearmind CEO Adi Zuloff-Shani and Clearmind VP of business development Mark Haden.

To register for the webinar, visit https://ibn.fm/EHdNb

For more information, visit https://ibn.fm/XDk3T

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of four patent families. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. For more information about the company, visit www.ClearmindMedicine.com.

Clearmind Medicine Inc. (CMNDF), closed Thursday’s trading session at $0.4655, even for the day. The average volume for the last 3 months is 375 and the stock's 52-week low/high is $0.3511/$0.73.

Hostess Brands Inc. (TWNK)

MarketBeat, Kiplinger Today, Schaeffer's, MarketClub Analysis, The Street, Trading Concepts, Trades Of The Day, Daily Trade Alert, Barchart, InvestorPlace, Market Intelligence Center Alert, BUYINS.NET, The Online Investor, StreetInsider, Marketbeat.com, Daily Wealth, CNBC Breaking News and Cabot Wealth reported earlier on Hostess Brands Inc. (TWNK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shares of Hostess Brands Inc. (NASDAQ:TWNK) traded at a new 52-week high today of $21.19. Approximately 204,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares.

Hostess Brands is the second- largest U.S. provider of sweet baked goods under the Hostess, Voortman, and Dolly Madison group of brands, including Twinkies, Cupcakes, Ding Dongs, Ho Hos, Donettes, and Zingers. In 2018, Hostess expanded its breakfast offerings with the purchase of Aryzta's breakfast assets (the Cloverhill business), including a branded business and private-label deals, and in 2020 entered the cookie category via the Voortman tie-up. Although its roots stem from the 1919 launch of the Hostess Cupcake, the company filed for bankruptcy in 2012. Investors purchased the brands and restarted production in 2013, followed by a 2016 initial public offering. Most products are sold in the U.S., although third parties distribute some product to Mexico, the United Kingdom, and Canada.

In the past 52 weeks, shares of Hostess Brands Inc. have traded between a low of $13.92 and a high of $21.19 and is now at $20.54, which is 48% above that low price.

Hostess Brands Inc. (NASDAQ:TWNK) defies analysts with a current price ($20.54) 53.7% above its average consensus price target of $9.50.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

Hostess Brands Inc. (TWNK), closed Thursday’s trading session at $20.51, up 6.7118%, on 12,452,717 volume. The average volume for the last 3 months is 12.451M and the stock's 52-week low/high is $13.94/$21.21.

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and process development services to the worldwide food and beverage, biotherapeutics and personal wellness industries, among others, today announced the commissioning of its first production-scale, patented Ultra Shear Technology(TM) (“UST(TM)”) platform. Per the update, the BaroShear MAX UST processing system was installed and commissioned in The Ohio State University College of Food, Agricultural and Environmental Sciences (“CFAES”). Together with the previously announced formation of the Food Industry Consortium, co-led by PBI and Ohio State, this completes one of the last remaining critical milestones in the UST platform deployment at Ohio State to serve the global food industry. “We expect to begin placing commercial processing units into the market during the third/fourth quarters of 2022, under a leasing and licensing model,” said Richard T. Schumacher, president and CEO of PBI. “As new and commercially-relevant UST applications are demonstrated, and Consortium members utilize their first rights to license them for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from equipment leases and consumables sales. In addition, PBI will drive the commercialization of these new applications amongst non-Consortium food companies worldwide and through multiple other major industries beyond food and beverages.” To view the full press release, visit https://ibn.fm/aBzy1

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Thursday’s trading session at $2.1, up 0.478469%, on 31,725 volume. The average volume for the last 3 months is 31,725 and the stock's 52-week low/high is $3.11/$7.29.

Recent News

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

  • Applied Magix’s product selection for consumers includes The MagixDrive Wireless CarPlay Adapter, The HomeKit Secure Video Camera with iCloud Storage, The Multipurpose Sensor with Alarm, The Environment and Motion Sensor, and The Window and Door Contact Sensor
  • The next phase of the ad campaign will ramp up the frequency of the ads and expand upon a higher interest profile of viewers
  • Smart home market size was valued at $98.24 billion in 2020 and is expected to grow at a CAGR of 23.59% from 2021 to 2028

Technology company SPYR (OTCQB: SPYR), dba SPYR Technologies, announced the expansion of a comprehensive marketing campaign for its subsidiary Applied Magix Inc. to additional markets, further broadening viewership for the brand (https://ibn.fm/UHVRD). SPYR operates through its Applied Magix Inc. subsidiary, developing and reselling Apple(R)-ecosystem-compatible products emphasizing a growing, multibillion-dollar Internet of Things (“IoT”) Smart Home and Connected Car markets.

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Thursday’s trading session at $0.075, up 48.8095%, on 650,350 volume. The average volume for the last 3 months is 650,350 and the stock's 52-week low/high is $0.59/$4.46.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Cannabis businesses often find it difficult to get banks willing to take them on as clients because of the risks posed by the federal prohibition of marijuana. Now new research has found that once a state legalizes cannabis, banking activity increases. While the study doesn’t directly link increased banking activity and state-level cannabis reform, it does imply the existence of the relationship. The study was conducted by researchers from Drexel University, the University of Arizona, Scripps College and San Diego State University. For their study, the researchers looked into banking trends in states that have legalized marijuana, examining the Federal Deposit Insurance Corporation’s bank regulatory filings in the 2011–2016 period. The researchers conducted an analysis of data from more than 150,000 bank-quarter observations sourced from almost 7,000 different banks located in 46 states. The group observed that as more state regulators issued statements supporting credit unions and banks that served the marijuana industry, financial institutions would become more optimistic about the chance that regulations will be adjusted in their favor with time. This would ultimately mean that cannabis sector actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) would have more options to choose from when they need different banking services.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Thursday’s trading session at $0.022, up 7.4481%, on 2,846,245 volume. The average volume for the last 3 months is 5,700 and the stock's 52-week low/high is $0.2778/$1.00.

Recent News

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

Tingo Inc. (OTC: IWBB) founder and CEO Dozy Mmobuosi was featured in a recent interview on The Daily Helping Podcast, a series focused on providing food for the brain, knowledge from the experts and tools to win at life. Hosted by entrepreneur and philanthropist Dr. Richard Shuster, the broadcast is available for on-demand listening on The Daily Helping. During the interview, Mmobuosi discussed his background in business leading up to the founding of Tingo as a way to provide agribusiness owners access to information and financial services. “We needed to create a niche market, because we didn’t have the resources to compete with Samsung and Nokia and the big brands at that time. I looked at various sectors and realized that the sector that needed all the help via technology was agribusiness,” Mmobuosi said. “Millions of undocumented agribusiness owners did not have a single bank branch in their village. It was clear that we must bring financial services to the rural communities of Nigeria. The fastest way to deploy services is through technology. We knew that the first thing to do was to make smartphones available to these farmers. We set up assembly lines in Abuja and Lagos. We made sure that each of these devices was preloaded with our mobile wallet, which these farmers would use to do their transactions.” To view the full press release, visit https://ibn.fm/41566

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Thursday’s trading session at $4, even for the day. The average volume for the last 3 months is 105 and the stock's 52-week low/high is $0.1488/$4.00.

Recent News

Hollywall Entertainment Inc. (OTC: HWAL)

The QualityStocks Daily Newsletter would like to spotlight Hollywall Entertainment Inc. (OTC: HWAL).

Hollywall Entertainment (OTC: HWAL), an innovative telecommunications and broadcasting company, has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media, and entertainment. Led by founder and CEO/President Darnell Sutton, a highly recognized visionary and award-winning business and social leader, the company maximizes rights to its music, film, television, software, and game libraries. Its subsidiary, Hollywall Development Company (“HWDC”), builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. “HWDC services, initiatives and investments include broadband and 5G networks, IoT, smart city technologies, energy, telemedicine, tele-education, transportation, clean water, waste management, and the development of green environments,” reads a recent article. “Hollywall Entertainment advanced its technological footprint through the formation of a new wholly owned subsidiary, HW Vision. HW Vision offers state-of-the-art services in the continuously growing digital marketplace, such as: 5G and fiber network installations, affordable high-speed internet access, telehealth services, domain hosting, web conferencing, managed internet services, nationwide unlimited talk, text, and data cellphone plans, and video broadcasting…. The Hollywall Entertainment Digital Music Network (‘HW Network’) has been constructed to sell single song and album downloads and music NFTs, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services.” To view the full article, visit https://ibn.fm/QXKeV

Hollywall Entertainment Inc. (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts.

Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City.

Hollywall Entertainment Inc. (Hollywall) Subsidiaries

Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment.

Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader.

HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide.

Hollywall Development Company (“HWDC”)

HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments.

HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities.

HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more.

HW Vision and Omnipoint Technology Inc.

Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

  • 5G and Fiber Network installation services
  • Affordable high-speed internet access
  • Telehealth services
  • Domain hosting
  • Web conferencing
  • Managed internet services
  • Nationwide unlimited talk, text and data cellphone plans
  • Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021.

Hollywall Entertainment Digital Music Network and Hollywall TV

The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry.

Market Outlook

Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries.

The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (https://ibn.fm/mgXIu).

Management Team

Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management.

Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few.

“Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine.

“After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release.

Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others.

Hollywall Entertainment Inc. (OTC: HWAL), closed Thursday’s trading session at $1.55, even for the day, on  volume. The average volume for the last 3 months is 1,600 and the stock's 52-week low/high is $0.1309/$1.20.

Recent News

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

  • NA legal cannabis market size projected to grow at CAGR of 16.6% from 2022 to 2028
  • More than 3,500 peer-reviewed scientific papers studying cannabis were published in 2020 alone
  • SGMD reaches key objectives, seeing key growth in 2021

After a year of impressive progress and growth, Sugarmade (OTC: SGMD) has established an enviable position in the legal cannabis market, a sector that is expected to see an estimated 16.6% growth in the coming years (https://cnw.fm/jxVvI).

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Thursday’s trading session at $0.0009, even for the day, on 28,578,869 volume. The average volume for the last 3 months is 28.579M and the stock's 52-week low/high is $3.59/$17.50.

Recent News

Nowigence Inc.

The QualityStocks Daily Newsletter would like to spotlight Nowigence Inc.

Nowigence has developed an innovative artificial intelligence (“AI”) platform called Pluaris(TM) that enables users to choose what information they want to receive and then delivers that information most effectively. “Pluaris is a proprietary, easy-to-use platform that assists users with reading and analyzing textual data. The platform is for those who want to automate the way they read, gather, learn, and recall information. Each feature of Pluaris is designed to accelerate the way we learn and improves the process of sharing knowledge with one another,” explains a recent article. “Pluaris generates an annotated data feed based on specified topics of interest and then automatically creates a permanent personal knowledge from a user’s feed and private uploads. The app has human-like capabilities for comprehending textual data and providing concise summaries and precise answers to questions, while also analyzing different data perspectives, discovering new connections, creating organized, nested notes, and allowing teams to work together by sharing in real-time from anywhere in the world. Nowigence is focused on simplifying the challenges of learning.” To view the full article, visit https://ibn.fm/uge7x

Nowigence Inc. is a fast-growing SaaS (Software-as-a-Service) company that develops and sells a ready-to-use artificial intelligence (AI) platform called Pluaris™ that automates reading and analysis of textual data. Individuals, teams, and enterprises can now quickly distill knowledge buried in narrative-intensive documents instantaneously from various data sources, both public and private.

Pluaris is created for those who want to read more in less time. It is a Personal Knowledge Management (PKM) tool that generates an annotated data feed based on your topics of interest and automatically creates a permanent personal knowledge base from your feed and private uploads. It has human-like capabilities for comprehending textual data. It summarizes, provides precise answers to questions asked, analyzes different data perspectives, discovers new connections, creates organized nested notes, and allows teams to work collaboratively by sharing in real-time from anywhere in the world to draw informed conclusions.

By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Nowigence puts the power of data science in the hands of consumers. It helps individuals, teams, and organizations to quickly build expertise on one or multiple topics by generating a trove of critical information.

Nowigence targets two user types that rely heavily on fast and accurate research as primary adopters of the Pluaris platform. The first is knowledge workers of all kinds – anyone whose job is to “think for a living” like marketing professionals, researchers, legal professionals, academics, journalists, editors, scientists, and other professionals. The second are individual users who are life-long learners, hobbyists, and enthusiasts of all stripes.

Rather than spending time reading information to gain knowledge from one source at a time, users of Pluaris can gain knowledge from hundreds or thousands of sources in seconds. Keyword-based search-and-retrieval applications don’t open documents, nor read their content, nor extract key points, conduct cause and effect analysis or answer questions specifically. Pluaris includes all those features and goes one step further, with its semantic capabilities to empower users with interpretations of retrieved information. Nowigence estimates this feature alone can save typical researchers between one and three hours per workday. The platform also reduces “noise” by extracting only important and relevant information on every topic being monitored or researched. This helps cut down on information overload, a major source of workplace stress.

Pluaris Builds Intelligence

The Problem

In the modern world, virtually everyone needs to consume a tremendous amount of text-based information, in both our personal and professional lives, but doing so is exceptionally challenging because of:

  • Information Overload: For virtually any significant topic of interest, the amount of textual information available and continually generated is vastly more than can be consumed by an individual.
  • Pervasive Distractions: Thanks to modern technology, we are constantly bombarded with new inputs (e-mails, instant messages, social media, and more) reducing our attention span, leading all too often to TL;DR (Too Long, Didn’t Read).
  • Highly Imperfect Human Recall: The information that we do find time to read is easily forgotten. Even if we retain some of the key insights, the details are almost certainly lost.

Even when working in teams, we often end up researching the same content as our colleagues, and too much of the information acquired by one individual is lost in translation with the communication process to others.

Pluaris

Nowigence has worked with stalwarts and pioneers in the fields of Machine Learning (ML) and Natural Language Processing (NLP) from its early days. The company was keen to solve the big problem of the information age – too much data exists and cannot be processed manually.

Pluaris is designed to be used by regular people from day one with no need for extensive training. The platform is used across different functions and sectors, adapting to clients’ ever-changing needs. Its state-of-the-art no code editing gives organizations the flexibility to improve and tailor their results without hiring data scientists, and real time information retrieval ensures the client never misses any piece of intelligence.

Pluaris adapts to the unique needs by which individuals absorb knowledge. It doesn’t impose structured or rigid methodology. Real time operation means that Pluaris will deliver outputs instantaneously with a click.

A Nowigence team of experts spent three years training Pluaris to understand the context of every sentence it reads. If Pluaris does make an error in contextual interpretation, the user can correct it, which will instantly give the correction precedence over the ML’s algorithmic outputs. This takes away the biggest criticism against AI/ML platforms, that annotating (labeling) data and developing training datasets to build models takes too much time and effort from internal teams.

Use Cases

I need to stay on top of the latest news for my industry. Pluaris automatically retrieves and analyzes news on your topics of interest every day, so you can quickly scroll through an annotated news feed on your phone, tablet or laptop, while finishing your morning coffee.

Example: A Pluaris enterprise customer was interested in tracking news and events in the telecom industry. Nowigence was able to quickly create and then fine-tune a list of topics to monitor. In less than a week, they had an annotated news feed covering the telecom industry available to their team.

I have to come up to speed on a new topic as quickly as possible. Upload a few related websites and documents to Pluaris and within minutes you are exploring this new area of interest, scanning the summaries, gaining new insights about this topic, and finding new keywords to broaden your search and deepen your understanding.

Example: A customer who was already using Pluaris for business intelligence decided to use his account to make improvements in his health after he received a report from his doctor of a high fasting blood sugar level.

  • He uploaded a few research reports to Pluaris, read through the summaries, and explored the annotated labels. Based on that analysis, he set up Pluaris to monitor topics such as “lowering fasting blood sugar” and “low glycemic food.”
  • From those results, he built an action list of daily habits for diet and fitness and, within a couple months, brought his fasting blood sugar level back down.

I want to be able to access the information I’ve read in the past and synthesize it with my current understanding. As you continue to add more and more information to the system over time, Pluaris never forgets. You are building a knowledge base of the information that is most relevant to you.

Example: A Pluaris user at one of the world’s largest aluminum mining companies was tasked with preparing talking points for her manager for an upcoming investor meeting. Over time using Pluaris, she had built a database of documents, including transcripts, notes, Q&A sessions, speeches, annual reports, and internal documents, some of which were from previous investor meetings. She was able to quickly explore that database through the Pluaris Dashboard and using various filters. She then pulled this information together in a Pluaris Notebook and shared that note directly with her boss.

Market Outlook

Pluaris users include:

  • Knowledge WorkersGartner estimates there are more than 1 billion worldwide as of December 2019.
  • Students in Higher Education: ICEF estimates there are 250 million worldwide as of 2020. This is Nowigence’s initial target group from a market penetration perspective.
  • Personal/Home Use: Statista estimates there are 4.7 billion active internet users worldwide as of January 2021.

Nowigence offers tiered pricing, starting at $10/month/user for individuals, while team and enterprise users, who have access to more features to facilitate collaboration and integrations to other enterprise tools, start at $45/month/user.

As a result, the Total Available Market (TAM) is more than a billion users and over $1 trillion. The Market Opportunity (the Serviceable Obtainable Market or SOM) for Nowigence is $11 billion in the combined PKM and Cognitive Computing space defined by Pluaris.

This market is growing rapidly too. The Cognitive Computing market alone was valued at $8.87 billion in 2018 and is projected to reach a value of $87.39 billion by 2026, growing at a CAGR of 31.6% from 2019 to 2026, according to Allied Market Research.

Nowigence offers differentiated value compared to other Personal Knowledge Management (PKM) tools, which have reached as many as 250 million users (Evernote) and have shown rapid adoption (Roam Research reached 60,000 users and $1 million ARR within 6 weeks of launching paid plans). Unlike Pluaris, these tools do not automatically monitor public or private sources to add to your knowledge base, nor do they provide summaries or extract intelligence. Pluaris differs from search engines as well, in that search engines do not access or store personal knowledge, and they also do not summarize or extract intelligence.

Management Team

Anoop Bhatia is the founder and CEO of Nowigence Inc., where he has worked full-time since 2015. Previously, he worked as a global operation strategic transformation leader for Momentive Performance Material (formerly GE Silicones). He has worked for over two decades in various General Electric companies across different countries, including the U.S., India, The Netherlands and Germany. He played a key role in establishing GE Silicones as the first-ever wholly owned foreign subsidiary established in India in 1996. He received his Bachelor of Engineering in Chemical Engineering from BITS in India and did his post-graduate studies in management from Heriot-Watt at Edinburgh in Scotland.

Gordon Haupt is the Chief Technology Officer at Nowigence. He has more than 20 years of experience building and leading diverse engineering and operations teams, and a strong technical background in machine learning, signal processing, and statistical data analysis, including applications in speech and text, biotechnology, and computer vision. He is a named inventor on 15 issued patents and is experienced in all phases of engineering development and operations. He holds a B.S. degree in Engineering Mechanics from the University of Wisconsin and M.S. and Ph.D. degrees from Stanford University in Aeronautics and Astronautics.

David Evans is the company’s acting CFO & General Counsel. As an attorney and licensed CPA in the state of New York, he has extensive experience in multistate and international tax policies and guidelines, federal taxation laws, mergers and acquisitions, including valuation of closely held businesses. He is a contributing author to the New York State Tax Service, a six-volume publication of NYS tax laws and regulations. His prior experience includes being a Managing Director for UHY Advisors LLC, a board member and chairperson of the Tax Division Executive Committee of New York State Society of Certified Public Accountants and a past president of the Estate Planning Council of Eastern New York. He holds degrees from Hofstra University and State University of New York at Buffalo.


Recent News

chart

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Commodities outperformed other asset classes last year, with the S&P Goldman Sachs Commodity Index rising by more than 30% to beat the U.S. equity index S&P 500, for the first time in 10 years. However, uncertainty over recovery from the pandemic caused major commodities to experience significant volatility, with some undergoing huge swings amid counteracting supply and demand narratives while others recorded new highs before dropping significantly. China played a role in some commodity markets, as the country is the second main importer of copper, coal, iron ore, crude oil and liquefied natural gas globally. The country’s impact was mostly felt in the metals sector, with spot iron ore hitting $235.50 per ton in May, as steel mills produced high amounts of the material. Chinese demand also influenced copper positively, with contracts in London hitting $10,747 per ton in the same month. When the nation shifted course on the output of steel, the price of iron ore dropped, with its spot price hitting $87 per ton in November. It would be interesting to be a fly on the wall in the boardrooms of companies such as Asia Broadband Inc. (OTC: AABB) as they hammer out their strategies for coping with the volatility that is likely to unfold in the commodities’ sector.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Thursday’s trading session at $0.1099, off by 2.4845%, on 6,459,279 volume. The average volume for the last 3 months is 6.459M and the stock's 52-week low/high is $0.9207/$6.42.

Recent News

Growth Capital Acquisition Corp. (NASDAQ: GCAC)

The QualityStocks Daily Newsletter would like to spotlight Growth Capital Acquisition Corp. (NASDAQ: GCAC).

  • Six LiDAR companies have gone public since 2020, raising $3.6+ billion as investors look for exposure to autonomous vehicles market
  • Cepton is merging with Growth Capital Acquisition Corp GCAC in the coming weeks in a deal valuing Cepton at $1.55 billion, with $231 million in pro forma cash on its balance sheet
  • Cepton has worked with the world’s biggest automotive OEMs, including General Motors and Ford, and garnered a $50 million investment for Japan’s Koito Manufacturing

As the race to fully autonomous vehicles (“AVs”) heats up, one particularly important pocket of the AV and advanced driver assistance systems (“ADAS”) markets is gaining momentum right along with it: LiDAR. LiDAR (short for “light detection and ranging”), developed for space applications and hyped for its potential in automotive applications, is moving beyond speculation and into revenue-generating reality. Investors are on board, with six LiDAR companies coming to market via special purpose acquisition companies (“SPACs”) since 2020, raising over $3.6 billion in the process, and another, Cepton, Inc.,  is dialed-in to go public on or about February 10th through a merger with the Growth Capital Acquisition (NASDAQ: GCAC) SPAC.

Growth Capital Acquisition Corp. (NASDAQ: GCAC), a publicly traded special purpose acquisition company listed on February 2, 2021, with $172.5 million in Trust, and Cepton Technologies Inc., a Silicon Valley innovator and leader in high performance MMT® lidar solutions, on August 5, 2021, announced their entry into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed ‘Cepton Inc.’ and is expected to be listed on the Nasdaq stock exchange under new ticker symbol ‘CPTN’.

The proposed business combination, which has been unanimously approved by the boards of directors of Cepton and Growth Capital, is expected to be completed early in the first quarter of 2022, subject to, among other things, approval by Growth Capital’s stockholders, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions.

Cepton Technologies Inc. is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s proposed merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Growth Capital Acquisition Corp. (NASDAQ: GCAC), closed Thursday’s trading session at $9.97, off by 0.1002%, on 2,227,694 volume. The average volume for the last 3 months is 2.192M and the stock's 52-week low/high is $0.3901/$2.45.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • The study is available for public viewing and is entitled “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants” (https://cnw.fm/Aq36i)
  • Dr. Richard van Breeman, who headed the independent study, explained that smoking and vaping cannabinoids are ineffective against preventing SARS-CoV-2, whereas oral delivery methods are effective
  • Lexaria has been studying and researching the oral delivery of compounds using its patented DehydraTECH(TM) technology, which enhances bioavailability and absorption, requiring less heat than smoking or vaping and leaving the cannabinoid compounds undamaged

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, commented on an independent January 10 study headed by lead research scientist Dr. Richard van Breeman, which discovered that cannabinoids can block cellular entry of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its emerging variants (https://cnw.fm/YcQIl). The study shows that smoking and vaping are likely ineffective measures, whereas oral delivery methods are.
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today provided an annual letter from CEO Chris Bunka and a thorough strategic update to all stakeholders. In the update, Bunka described Lexaria’s key area of focus to improve the company’s understanding of the capabilities of its ground-breaking DehydraTECH(TM) drug-delivery technology to enhance its abilities to commercialize and profit from this technology platform. “DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform,” Bunka explains in the letter. “Expecting entire industries to change overnight to adopt a revolutionary new process is not realistic: it takes time, evidence and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation… Before 2022 ends, we expect to have at least one major regulatory advancement such as an IND program approval, or one major new industry partner. We believe either of those will support what could be significantly higher valuations. If we are able to achieve more than one of these advancements…so much the better.” To view the full press release, visit https://ibn.fm/MqHa4.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday’s trading session at $4.17, off by 2.5724%, on 51,239 volume. The average volume for the last 3 months is 51,239 and the stock's 52-week low/high is $0.289/$1.65.

Recent News

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

Nemaura Medical (NASDAQ: NMRD) is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device. “As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT devices to MySugarWatch Limited, its U.K. licensee. MySugarWatch Limited intends to market sugarBEAT via a subscription-based diabetes coaching and management service that targets over 4.9 million diabetics and 13.6 million people with an increased risk of contracting type 2 diabetes in the U.K.,” reads a recent article that also contains comments by Nemaura CEO Dr. Faz Chowdhury. “This initial shipment of sugarBEAT CGM devices to our U.K. licensee allows the company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” said Dr. Chowdhury. “Starting in the U.K., patients with type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence and outcome.” To view the full article, visit: https://ibn.fm/TnjIH

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Technologies

Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Thursday’s trading session at $4.0871, off by 1.2778%, on 13,059 volume. The average volume for the last 3 months is 13,059 and the stock's 52-week low/high is $0.0269/$0.231.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

PTSD and traumatic brain injuries are the primary indications affecting veterans, with almost 500,000 troops living with these diseases. However, thousands more have also been diagnosed as having illnesses that may be connected to toxic waste and environmental hazards. Hundreds of veterans are fighting glioblastoma, with some succumbing to the fatal disease. Glioblastoma is a common and aggressive type of cancer affecting the brain. It occurs in an individual’s spinal cord or brain. Research done on veterans and military personnel to determine why glioblastoma rates are higher in the active-duty population in comparison to the population in general haven’t produced any conclusive results. In an interview, the VA revealed that the rate at which claims are approved was about 31% for veterans of the Gulf-war period while that of post-9/11 military veterans was better, at 57%. Many hope that claiming benefits for brain cancer will get easier after an announcement made by the VA last year that it would review if various cancers needed to be fast-tracked for disability benefits. If this happens, more military veterans could stand a chance of benefiting from the brain cancer treatments commercialized by entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday’s trading session at $0.57, off by 9.753%, on 209,902 volume. The average volume for the last 3 months is 209,902 and the stock's 52-week low/high is $0.022/$0.70.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.